NHS England | June 2018 | NHS England strikes deal on new NICE recommended lung cancer immunotherapy drug
NHS England have announced it will make lung cancer drug pembrolizumab available for routine use on the NHS. Trial results show pembrolizumab extends life for certain adults with lung cancer for more than a year.
According to NHS England Pembrolizumab is the first drug to exceed the new budget impact threshold for new products costing more than £20 million a year. The drug, which is also called Keytruda, would have cost around £84,000 per patient at its full list price. NHS England and MSD have agreed a confidential arrangement for reimbursement which will enable NICE to recommend it be routinely available on the NHS (NHS England).
The full announcement is available at NHS England
NICE confirms that it will recommend that breakthrough cancer drugs palbociclib and ribociclib be provided on the NHS for women with advanced breast cancer| story via OnMedica
There are around 45,000 new diagnosis of breast cancer each year in England and it is estimated that around 8,000 of these people would be eligible for treatment with either palbociclib or ribociclib.
In draft guidance, NICE said breast cancer patients should have routine access to these two life extending drugs after a new deal with their manufacturing companies who agreed to lower the price and who gave more evidence for their effectiveness.
NICE said that although there were some uncertainties on how long they extend the life expectancy of people with this type of breast cancer, these promising new drugs were found to stall the growth of cancer for an extra 10 months on average.
- More information at NICE
- Full story via OnMedica
- Related: Thousands to benefit as ‘breakthrough’ breast cancer drugs approved for NHS use | The Guardian
Patients getting faster access to cancer drugs as NICE approves three quarters of the Cancer Drugs Fund | NICE
Liver cancer drug, sorafenib has been approved for routine NHS use, marking three quarters of the way through the Cancer Drugs Fund (CDF) without a negative decision.
NICE has recommended sorafenib, also known as Nexavar, made by Bayer to be routinely available for some patients on the NHS.
Sorafenib is one of the 24 drugs NICE was asked to appraise from the CDF, and all have been approved so far for routine NHS use.
Its positive recommendation means that NICE is three quarters of the way through the CDF with 18 drugs now approved.
Companies, like Bayer have provided discounts and in some cases additional evidence meaning the drugs can be considered as cost effective for routine NHS.
Read the full news story here
The NHS in England will soon be able to routinely fund the use of trastuzumab emtansine for people with certain categories of breast cancer, the National Institute for Health and Care Excellence (NICE) has announced in new draft guidance | OnMedica
NICE’s decision means that, by late summer, more than a thousand women and men could benefit from the drug.
HER2-positive breast cancer accounts for about a fifth of the roughly 41,500 women and 300 men who are diagnosed with breast cancer each year in England, but HER2-positive tumours are typically more aggressive than other types of breast cancer. The targeted treatment trastuzumab (Herceptin) is only effective for this type of breast cancer. Trastuzumab emtansine (Kadcyla) is licensed for the treatment of locally advanced or metastatic HER2-positive breast cancer, after trastuzumab and a taxane, taken either in combination or separately.
Currently, trastuzumab emtansine – which at full list price costs about £90,000 per patient – is only available on the NHS through the Cancer Drugs Fund (CDF). But NICE revealed yesterday afternoon that the drug’s manufacturer Roche had agreed a new commercial access arrangement with NHS England. When NICE factored this confidential agreement into a new clinical and cost-effectiveness analysis, also applying end-of-life criteria, it concluded that it can now recommend the drug as cost effective for routine use on the NHS.
NICE has published a new quality standard Haematological cancers (QS150).
This quality standard covers diagnostic reporting and the organisation of haematological cancer services for people of all ages (including children and young people) and managing haematological cancers in adults and young people (aged 16 and over). It describes high-quality care in priority areas for improvement.
Expert cancer clinicians have condemned a preliminary decision by the National Institute for Health and Care Excellence (NICE) not to approve use of the drug nivolumab (Opdivo) for the treatment of head and neck cancer on the NHS | OnMedica
NICE has today issued new draft guidance which does not recommend nivolumab in this way, saying that it is not cost-effective.
Nivolumab is administered intravenously every two weeks and the drug works by blocking a protein on the surface of cells known as PD-L1, which reduces the activity of the body’s immune cells. There is more PD-L1 on cancerous cells which stops the immune system from attacking the tumour.
NICE said the anticipated marketing authorisation for nivolumab was for treating squamous cell carcinoma of the head and neck which has progressed during or after platinum-based chemotherapy.
The watchdog found that the evidence showed a significant improvement in overall survival rates in the short term after nivolumab. However, its value for money was considerably above that which is usually a cost-effective use of NHS resources.
Read the full commentary here
NICE draft guidance is available here